Keverprazan, a novel potassium-competitive acid blocker: single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

CONCLUSION: Keverprazan is tolerable, and provides significant stable and lasting inhibition efficacy of intragastric acidity at 20 mg.PMID:37666458 | DOI:10.1016/j.ejps.2023.106578

Source: European Journal of Pharmaceutical Sciences - September 4, 2023 Category: Drugs & Pharmacology Authors: Sufeng Zhou Lijun Xie Chen Zhou Yuqing Zhao Lu Wang Sijia Ding Juan Chen Bei Zhu Mei Su Feng Shao Source Type: research